Company Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States.
The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections.
Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | David Luci |
Contact Details
Address: 259 Liberty Avenue Staten Island, New York 10305 United States | |
| Phone | 917 533 1469 |
| Website | acurxpharma.com |
Stock Details
| Ticker Symbol | ACXP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001736243 |
| CUSIP Number | 00510M203 |
| ISIN Number | US00510M2035 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David P. Luci CPA, Esq., J.D. | Co-Founder, President, Chief Executive Officer, Corporate Secretary and Director |
| Robert J. DeLuccia | Co-Founder and Executive Chairman |
| Robert G. Shawah CPA | Co-Founder and Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 11, 2025 | 10-Q | Quarterly Report |
| Aug 5, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 4, 2025 | DEF 14A | Other definitive proxy statements |
| Jul 31, 2025 | 8-K | Current Report |
| Jul 24, 2025 | PRE 14A | Other preliminary proxy statements |
| Jul 23, 2025 | EFFECT | Notice of Effectiveness |
| Jul 17, 2025 | 8-K | Current Report |
| Jul 15, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jul 9, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 27, 2025 | D | Notice of Exempt Offering of Securities |